P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

Original reporting
Published Aug 17, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PIIIBullishMed
01

Why it matters

The transcript highlights a shift toward more predictable earnings, with improved payer economics, lower medical cost trend versus the 2025 baseline, and a raised 2026 adjusted EBITDA outlook.

02

Market read

Traders can update valuation and positioning based on the raised full-year adjusted EBITDA range and the disclosed improvement in underlying profitability and medical cost trend.

03

What to watch

At-risk membership fell 10% while revenue rose 9%, so investors may scrutinize whether growth is sustainable without further membership changes or settlement tailwinds.

Relevance 9/10Novelty 8/10Timing: after-hours earnings call transcript, published Aug. 17

Background

P3 Health Partners is a Medicare-focused healthcare services company that reports results using adjusted EBITDA and underlying medical margin metrics tied to capitated revenue and medical cost trends.

Company-level read

Ticker impact

$PIIIBullishMedium confidence
Context

P3 Health Partners reported Q2 2026 revenue of $386.4M, adjusted EBITDA of $54.4M, and raised full-year 2026 adjusted EBITDA guidance to $80M-$110M.

Expected impact

Near-term bias higher as traders price in the raised 2026 adjusted EBITDA range and improved medical cost trend.

Evidence & confidence

The call discloses multiple decision-relevant datapoints: net income improvement, underlying adjusted EBITDA turning positive, and explicit full-year guidance ranges, which typically drive earnings revisions and sentiment.

Market effects

Reinforces the managed-care services narrative that operational discipline and payer economics can stabilize earnings even with membership rationalization.

Nebraska expansion plan (services in 2027, full-risk in 2028) may affect local provider network expectations.

Limited, as the disclosure is company-specific within US Medicare Advantage care delivery.

Counterpoint

A large portion of reported profitability is supported by payer settlements and prior-year development, which may not recur at the same magnitude.

Key entities

  • P3 Health Partners

    Reported Q2 2026 results and raised full-year 2026 adjusted EBITDA guidance; discussed underlying profitability and medical cost trend drivers.

  • Aric Coffman

    CEO who attributed results to structural and operational contract, market, and operating-model changes.

  • Leif Pedersen

    Commented on seasonal medical expense trends and stated the core business is generating positive adjusted EBITDA excluding settlements.

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30